Zhenya Lindgardt Sells 38,899 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 38,899 shares of the firm’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total value of $364,483.63. Following the completion of the sale, the chief executive officer now directly owns 908,104 shares of the company’s stock, valued at approximately $8,508,934.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, February 6th, Zhenya Lindgardt sold 27,997 shares of Sera Prognostics stock. The shares were sold at an average price of $8.03, for a total value of $224,815.91.

Sera Prognostics Price Performance

Sera Prognostics stock opened at $9.46 on Thursday. Sera Prognostics, Inc. has a one year low of $1.52 and a one year high of $10.44. The business has a fifty day moving average of $8.40 and a two-hundred day moving average of $5.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new position in shares of Sera Prognostics during the 1st quarter worth $39,000. StepStone Group LP acquired a new position in shares of Sera Prognostics during the 4th quarter worth $61,000. Goldman Sachs Group Inc. acquired a new position in shares of Sera Prognostics during the 1st quarter worth $41,000. Frontier Wealth Management LLC acquired a new position in shares of Sera Prognostics during the 1st quarter worth $30,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Sera Prognostics during the 1st quarter worth $46,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.